REPL Stock Plunges As FDA Rejects Key Melanoma Therapy

Replimune Group Inc. stocks have been trading down by -14.69 percent following negative sentiment over its latest clinical trial update.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading REPL

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways For REPL Traders

The FDA issued a Complete Response Letter rejecting Replimune’s BLA for RP1 plus nivolumab in advanced melanoma, saying trial data were not strong enough to prove the drug works.
Shares of Replimune Group Inc. collapsed about 19% on heavy volume, were halted around $4.76, and one legal filing cites a total slide of roughly 64% tied to the same news.
Management says that without timely accelerated approval for RP1, the program is no longer viable, and Replimune will cut jobs and sharply scale back U.S. manufacturing.
Major brokers including Cantor Fitzgerald, Piper Sandler, JPMorgan, and HC Wainwright downgraded REPL, clustering around a $4 price target and a Hold consensus.
Law firms Pomerantz LLP and Johnson Fistel launched securities‑fraud investigations into Replimune, focusing on whether traders were misled about resolving earlier FDA concerns.

Live Update At 14:02:41 EDT: On Tuesday, May 05, 2026 Replimune Group Inc. stock [NASDAQ: REPL] is trending down by -14.69%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

REPL has turned into a classic fallen‑biotech chart. On 2026/04/10, Replimune Group Inc. was trading near $5–$6 before the FDA’s Complete Response Letter, then slid hard and never really bounced back. In recent sessions, REPL has closed between roughly $2.40 and $3.03, with the latest daily close at $2.585 after a weak, choppy session.

Intraday on the most recent day, REPL opened at $3.02, briefly pushed to $3.09 in the morning spike, then faded steadily to that $2.585 close. The 5‑minute candles show a stair‑step drift lower from the high $2.80s into the mid‑$2.50s, with no clear reclaim of the morning range. That tells traders supply is still hitting every pop.

More Breaking News

Fundamentally, Replimune Group Inc. is a pre‑revenue biotech, so the story is all about cash and burn. REPL reported about $124.7M in cash at 2025/12/31 and $269.1M including short‑term investments. Operating cash outflow for the quarter was about $66.0M, and free cash flow was around -$66.1M. With a price‑to‑book around 0.98 and book value per share near $2.55, REPL now trades almost exactly at stated equity, signaling the market is heavily discounting the pipeline after the FDA setback.

Why Traders Are Watching REPL Now

REPL is on every active biotech trader’s radar because the story flipped almost overnight. Replimune Group Inc. built its pitch around RP1, also called vusolimogene oderparepvec, in combination with nivolumab for advanced cutaneous melanoma after PD‑1 failure. The FDA originally gave feedback that supported a single‑arm trial and an accelerated approval path. Many traders anchored to that.

Then a new FDA review team stepped in and issued a Complete Response Letter, saying the IGNYTE trial data were not adequate or interpretable enough to show effectiveness. REPL disclosed that the agency’s stance effectively reversed or contradicted earlier guidance. For momentum traders, that’s brutal: the original edge case for accelerated approval just vanished.

The market reaction was immediate. REPL shares plunged about 19% on heavy volume, dropped to $4.76 intraday, and were halted for pending news. Later legal filings reference a roughly 64% collapse tied to the same FDA blow‑up, showing how far sentiment fell as more details surfaced. Replimune Group Inc. then told the Street that without timely accelerated approval, RP1 is no longer commercially viable. The company plans job cuts and a large pullback in U.S. manufacturing.

Wall Street piled on. Cantor Fitzgerald, Piper Sandler, JPMorgan, and HC Wainwright all cut ratings on REPL to Neutral, Underweight, or even Sell, with a consensus Hold and mean target around $4. Two law firms, Pomerantz and Johnson Fistel, opened investigations into whether Replimune misled traders about solving prior FDA issues. That combination of regulatory shock, analyst downgrades, and legal overhang is exactly the type of volatility cluster short‑term traders track closely.

Conclusion

For active traders, REPL is now a high‑risk, headline‑driven biotech with a wounded flagship program. Replimune Group Inc. still has cash, but the RP1 path in melanoma has been hit by not one, but two FDA Complete Response Letters. The agency again called the IGNYTE data inadequate, and a new review team walked back earlier comfort with a single‑arm design. That forces the market to reconsider how much value, if any, to assign to this asset.

On the tape, REPL trading shows classic post‑crash behavior: heavy sell‑offs on the news, followed by low‑volume bounces that stall near prior breakdown levels. The stock now hovers around book value, which can attract bargain hunters, but the ongoing Pomerantz and Johnson Fistel investigations create another layer of uncertainty. Any new headline on those probes can trigger sharp moves in either direction.

For short‑term players, Replimune Group Inc. becomes a “react, don’t predict” setup. The key is to map levels from the initial gap‑down day and use strict risk management around them. As Tim Sykes likes to remind traders, “The market doesn’t care about your opinion, just your discipline. Trade the price action, cut losses quickly, and don’t marry a stock.” In the same spirit of disciplined trading, As Tim Bohen, lead trainer with StocksToTrade says, “If you’re still guessing at the end of your analysis, it’s probably not a trade worth taking.” REPL is a live case study in that mindset. This coverage is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!